Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

286
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
286
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

789
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

440
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
440
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

296
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
296
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney Injury, Dialysis, and Mortality with Vancomycin Plus Piperacillin-Tazobactam or Cefepime.

International journal of antimicrobial agents·2026
Same author

Natural language processing (NLP)-assisted assessment of neurologic severity and functional outcomes in factor Xa inhibitor-related intracranial hemorrhages.

Frontiers in neurology·2026
Same author

Repurposing Purine Analog Antivirals to Modulate Serum Uric Acid: Evidence From Real-World Data.

Clinical and translational science·2026
Same author

Evaluating methylphenidate as a potential treatment for cocaine use disorder: a propensity score-matched study.

The American journal of drug and alcohol abuse·2026
Same author

Evaluating the Impact of Blood-Brain Barrier-Penetrant ACE Inhibitors on HIV-Associated Neurocognitive Disorders.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study.

Clinical rheumatology·2025

Related Experiment Video

Updated: Mar 9, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K

Is cardiovascular risk a concern when prescribing azithromycin?

S Scott Sutton1

  • 1S. Scott Sutton is a professor in the Department of Clinical Pharmacy and Outcomes Sciences in the South Carolina College of Pharmacy at the University of South Carolina in Columbia, S.C. The author has disclosed no potential conflicts of interest, financial or otherwise.

JAAPA : Official Journal of the American Academy of Physician Assistants
|December 30, 2016
PubMed
Summary

The FDA updated azithromycin labeling due to potential cardiac risks like QT prolongation, especially in older adults. Further research is needed to clarify these cardiovascular effects.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.6K

Related Experiment Videos

Last Updated: Mar 9, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.6K

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Safety

Background:

  • Azithromycin labeling updated by the FDA.
  • Concerns raised regarding cardiac risks, including QT prolongation and dysrhythmias.
  • An initial study suggested an increased mortality risk with azithromycin compared to amoxicillin.

Purpose of the Study:

  • To inform healthcare providers about updated azithromycin safety information.
  • To highlight the potential for cardiac adverse events associated with azithromycin use.
  • To contextualize the FDA's labeling update within existing research.

Main Methods:

  • Review of FDA-initiated studies and existing literature on azithromycin's cardiovascular effects.
  • Analysis of package labeling changes.
  • Assessment of comparative risk data.

Main Results:

  • FDA updated azithromycin labeling to include risks of prolonged cardiac repolarization and QT prolongation.
  • Increased risk of cardiac dysrhythmias and torsades de pointes identified, particularly in elderly patients.
  • Conflicting cardiovascular findings across different azithromycin studies necessitate further investigation.

Conclusions:

  • Azithromycin carries a risk of serious cardiac events, including QT prolongation and potentially fatal arrhythmias.
  • The clinical significance of these cardiac risks requires additional research.
  • Azithromycin remains a valuable antibiotic for bacterial infections when clinically indicated.